iZafe Group's CFO, Marius Sandberg, has today acquired 177,793 B-shares in the company at a value of SEK 34,909 (SEK 0.196 per share).

The acquisition was completed today, November 14, bringing Marius Sandberg's total shareholding in iZafe to 177,983 B-shares.
"As the new CFO, I see the potential that exists in iZafe, and with this share purchase, I am demonstrating my confidence in the company’s future. I look forward to being part of iZafe’s growth journey and to continue working towards creating value for our shareholders and contributing to the company’s long-term success," says Marius Sandberg, CFO of iZafe Group.

iZafe Group AB (publ.) presents today, November 1, its report for the third quarter.

Financial Performance in Summary

  • Total revenue for the quarter amounted to 2,434 (927) TSEK, an organic growth approximately 2.5 times higher than the corresponding quarter of the previous year.
  • The operating result (EBIT) for the quarter amounted to -4,148 (-5,012) TSEK.
  • The operating profit before depreciation (EBITDA) for the quarter amounted to -3,166 (-3,159) TSEK.
  • The result after financial items for the quarter amounted to -4,955 (-5,004) TSEK.
  • The period’s cash flow from operating activities amounted to -2,913 (-2,854) TSEK.
  • Earnings per share for the quarter before / after dilution amounted to -0.02 (-0.02) SEK.
  • Equity per share at the end of the period amounted to 0.1 (0.2) SEK.
  • The solidity at the end of the period amounted to 58.0 (82.9) percent.

Significant events during the quarter

  • iZafe Group AB received an order for 500 Dosell units from its partner Ti Medi. This order is part of Ti Medi’s launch of a new concept, where Dosell is integrated with their dose-packaging machines to offer pharmacies a complete solution that improves patient medication adherence.
  • iZafe Group AB entered into a loan agreement for 5.5 MSEK with Exelity AB, which replaces the previous TO14B series warrants that were canceled due to high costs and uncertainty. The loan will be used to increase production volumes and intensify sales and marketing efforts, supporting the company’s long-term growth strategy.
  • iZafe Group AB has entered a three-party collaboration with Zafe Care Systems AB and Sensorem AB. The partnership combines Dosell with Sensorem’s safety alarms to enhance independence and safety in medication management, even outside the home, strengthening both freedom and quality of care in the healthcare sector.
  • iZafe Group AB has entered a partnership with Randstad in Norway to streamline the implementation of Dosell in Norwegian municipalities. Through Randstad’s presence and expertise in staffing, sustainable implementation and improved medication management are ensured, potentially leading to cost savings in healthcare.

Significant events after the end of the quarter

  • iZafe Group AB launched Dosell in Spain in collaboration with Ti Medi. At an event in Granada, Dosell was presented to Ti Medi’s network of 1,400 pharmacies. This launch marks an important milestone and signifies that Dosell is now commercially available in Spain, with the first units to be in use shortly. The collaboration aims to improve medication management and adherence among patients.

Comments from CEO
It is with great pleasure that I can state that we are in a very exciting and expansive phase. Our growth journey has truly gained momentum, and we are seeing clear results from our efforts to revolutionize healthcare through innovation and digitalization. The number of active units has increased by 29% compared to the previous quarter, and we have now delivered approximately 2,000 Dosell units to our partners. Our mission to digitalize healthcare and ensure the right medicine at the right time is starting to take shape in earnest.
 
Spain – A New Market with Great Potential
Earlier this year, we received an order for 500 Dosell units from our partner Ti Medi, and I am proud to announce that Ti Medi has now launched our innovative solution in the Spanish market. Together with Ti Medi and their 1,400 pharmacies, we are offering a unique solution that combines their dose-packaging machines with our medication robot, Dosell. This is a groundbreaking offering that will change how pharmacists monitor patient medication adherence, leading to better healthcare. This launch is our first major venture outside Sweden targeting the consumer market, and next year, we look forward to extending this offering to the healthcare sector as well.
 
New Phase – Clearer Forecasts and Increased Insight into Growth Potential
We are now entering a new and very important phase for iZafe Group. For the first time, we can forecast our growth based on actual key metrics, showing how the number of active Dosell units increases each month. This means that, starting from the next quarterly report, we will be able to present clear and credible forecasts that give you, our existing shareholders, and potential new investors, an even better understanding of the company’s future potential. This is an important milestone for us and something that will further strengthen our position moving forward.
 
More Markets and Continued Growth
Our expansion is not limited to Spain. We have seen strong demand from both Swedish municipalities and our international markets. The Netherlands and Sweden have continued to deliver steady growth, and we expect Norway and Finland to follow suit during the final quarter. Our business model is based on active units with recurring revenue, and we are working diligently to ensure that we can meet increasing demand and create steady growth month by month.
 
At the same time, our total revenue has tripled compared to the first three quarters of last year, further confirming the positive development.
 
Strategic Partnerships and Innovation
We have also taken an important step forward with our strategic three-party collaboration with Zafe Care Systems and Sensorem. Together, we offer a holistic solution for increased independence and security in medical care. Through the integration of Sensorem’s safety alarms with Dosell, we can ensure that users are reminded to take their medicine even when they are far from home, creating a safer daily life for those who rely on continuous medication. This is a strong symbol of our vision to create solutions that not only streamline healthcare but also give users greater freedom and security in their everyday lives.
 
Opportunities for the Future
We now look forward to further strengthening our presence, with more Dosell units being implemented in municipalities and healthcare institutions across Europe. Particularly exciting is our expansion in Norway, where we have entered into a partnership with Randstad to ensure an efficient and successful implementation of our solutions. We are confident that this partnership will help us ensure high quality in the transformation process and that our solutions reach as many users as possible.
 
Thanks to increased sales, strong partnerships, and innovative solutions, we are now facing a bright future with continued growth and opportunities. I would like to extend my heartfelt thanks to all our employees, partners, and shareholders for your commitment and support – together, we are making a real difference.
 
Thank you for being part of our journey.

Anders Segerström
Chief Executive Officer, iZafe Group

iZafe Group AB (“iZafe Group”) is thrilled to announce the grand launch of Dosell in collaboration with Ti Medi, taking place in Granada on October 22-23. The event marks a pivotal moment as Ti Medi introduces its innovative concept, combining the Savioo Website and Dosell medication dispenser, to the Spanish market. Attendees at the event include 150 Ti Medi's customers, who will gain exclusive insights into Dosell and its transformative impact on medication adherence. Ti Medi's extensive network includes around 1,400 pharmacies, which significantly expanding the potential reach and impact of this innovative concept.

This launch paves the way for Dosell to become commercially available in Spain, with the first active units expected to be operational shortly. The collaboration between iZafe Group and Ti Medi represents a breakthrough in addressing the critical need for efficient and reliable medication management. The event highlights the tireless efforts and commitment of both teams in bringing this solution to life.
 
“We are incredibly proud to see the result of months of hard work and dedication as Dosell is now launched in Spain. This is a significant milestone, not only for iZafe Group but for the entire healthcare sector in Spain. Dosell will make a substantial difference in patients’ lives by simplifying their medication management. The launch also serves as strong proof of our successful partnership with Ti Medi, and we look forward to following Dosell’s impact on the Spanish market,” says Anders Segerström, CEO of iZafe Group.
 
The event in Granada serves as the official introduction of Dosell to Ti Medi's extensive network of clients, showcasing its potential to revolutionize medication adherence through an integrated system. The comprehensive approach, which includes Ti Medi's packaging technology alongside Dosell, empowers pharmacies to monitor patients’ adherence with unprecedented efficiency.
 
Marc Tarruell Tibau, CEO of Ti Medi, adds, “Bringing Dosell into our solution portfolio is a game changer. Our customers will now be able to offer an all-in-one package that significantly enhances medication management. This integration is a key step forward in improving adherence and, ultimately, patient outcomes.”
 
With Dosell now available on the Spanish market, iZafe Group is poised to continue expanding its footprint in Europe, with Spain set to become one of the key markets for the company's innovative healthcare solutions.

iZafe Group AB ("iZafe Group") today announces a strategic partnership with Randstad, a global leader in healthcare personnel services, to launch a new initiative in Norway. This collaboration aims to ensure the long-term and effective implementation of Dosell's medication dispensers across Norwegian municipalities by providing the right personnel with comprehensive training and ongoing support.

As part of our relaunch in Norway, we recognize that the most critical factor for success is effective implementation. Randstad will play a central role in managing significant parts of this implementation, regardless of which partner in Norway sells Dosell.

With the increasing demand for efficient medication management in healthcare systems, Dosell's partnership with Randstad combines technological innovation with human expertise. Randstad's strong presence in nearly all municipalities in Norway allows for tailored staffing solutions and professional development programs, ensuring that healthcare professionals are fully trained to use Dosell's cutting-edge medicine dispenser. The initiative aims to enhance patient safety and optimize medication management throughout Norway's healthcare sector.

"We are very excited to launch this partnership with Randstad in Norway, a country where we see great potential for improving medication management through our technology," says Anders Segerström, CEO of iZafe Group. "By collaborating with Randstad, which has an extensive network and deep understanding of the local healthcare landscape, we can ensure that our medicine dispenser is implemented effectively and sustainably across Norwegian municipalities. This partnership is about combining the best technology with the right people to deliver long-term, high-quality healthcare solutions."

Per Arne Lien, Manager of Health Technology at Randstad, commented, "Our extensive presence in the majority of the municipalities in Norway allows us to uniquely understand the local needs and challenges of healthcare providers. Partnering with Dosell enables us to support Norwegian municipalities with experienced, well-trained professionals who can ensure the successful integration and long-term use of Dosell's medicine dispenser. Together, we are committed to advancing healthcare quality and patient outcomes in Norway through innovation and expertise."

The partnership will begin with a pilot program across several municipalities in Norway, focusing on delivering comprehensive training for healthcare professionals and providing continuous support and advisory services. This approach ensures that Dosell's technology is not only effectively implemented but also continuously optimized to meet the evolving needs of healthcare providers and their patients.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

About Randstad
Randstad is a global leader in HR services, specializing in staffing, talent management, and workforce solutions. In Norway, Randstad has a significant presence across nearly all municipalities, providing skilled professionals to support local healthcare services and other sectors.

iZafe Group AB ("iZafe Group") today announces a strategic tripartite collaboration with Zafe Care Systems AB and Sensorem AB. This partnership, building on previous successes in municipal care, represents a significant step forward in providing users with increased independence and safety in their medication management, regardless of their location.

Dosell has already established itself as a leading solution for safe and efficient medication management. By automating the dosing and distribution of medications, Dosell reduces the risk of taking the wrong medication, double dispensing, and frees up valuable time for healthcare staff. Now, with the integration of Sensorem’s mobile safety alarm, the next step is being taken to offer a holistic solution that places the user’s freedom and safety at the forefront.

The Sensorem watch not only serves as a reminder to take medications, such as insulin, but also functions as a mobile safety alarm that is constantly present. If a user is far from home and does not take their medication on time, an alert is sent directly to the watch, ensuring that the appropriate actions can be taken immediately. This creates a unique combination of security and independence, allowing the user to live an active life without worrying about their health.

“With this collaboration between iZafe Group, Zafe Care Systems, and Sensorem, we are offering not just a solution for safe medication management, but also a new level of independence and security for users. Our vision is for our products to be easily integrated and become part of a comprehensive solution, showcasing the strength of Dosell. By developing products and services that can seamlessly interact with other systems, we aim to create the best possible solution for both users and healthcare professionals, without the need to manage multiple apps and systems,” says Anders Segerström, CEO of iZafe Group AB.

Per la Fleur, CEO of Zafe Care Systems AB, adds: “By combining Dosell’s reliability with Sensorem’s mobile safety alarm, we are creating an unbeatable solution that not only improves the quality of care but also gives the user the freedom to live an independent life. This is the future of healthcare technology, and we are proud to be part of this development.”

Bobo Delemark, CEO of Sensorem AB, emphasizes: “The Dosell medication dispenser and Sensorem’s mobile safety alarm together form a unique combination that is beneficial for both the user and the municipality. The user can, for example, be in a different location and be notified that medication needs to be taken (both verbally and in text), and healthcare staff can initially call the mobile alarm to ensure the medication is taken.”

About Zafe Care Systems AB: Zafe Care Systems AB specializes in developing technological solutions for healthcare and social care. With a focus on user-friendliness and safety, Zafe delivers innovative products that improve the quality of care and increase the independence of users. www.zafe.se

About Sensorem: Sensorem develops mobile safety alarms and security solutions that provide users with increased safety and freedom in their daily lives. By combining advanced technology with ease of use, Sensorem offers products that are both reliable and flexible. https://www.sensorem.com/sv/

iZafe Group AB (publ.) presents today, August 30, its report for the second quarter.

Financial Performance in Summary

  • Net sales for the quarter amounted to SEK 168 thousand (SEK 403 thousand). The decrease in sales during the quarter is primarily attributable to an adjustment of previously invoiced amounts from Q1. Approximately 5% of the units produced did not meet quality standards and have therefore been adjusted in this quarter, with invoicing planned for a later date. The quarter’s sales reflect revenue from the sale of the digital medication robot Dosell and the medical device Pilloxa.
  • The operating result (EBIT) for the quarter amounted to SEK -4,011 thousand (SEK -5,097 thousand).
  • The operating profit before depreciation (EBITDA) for the quarter amounted to -3,027 (-3,135) TSEK.
  • The result after financial items for the quarter amounted to -4,037 (-5,136) TSEK.
  • The period’s cash flow from operating activities amounted to -4,155 (-2,253) TSEK.
  • Earnings per share for the quarter before / after dilution amounted to -0.02 (-0.02) SEK.
  • Equity per share at the end of the period amounted to 0.1 (0.2) SEK.
  • The solidity at the end of the period amounted to 73.3 (82.4) percent.

Significant events during the quarter

  • The Board of Directors of iZafe Group has resolved on a directed issue of 25 million B shares, raising SEK 5 million for the company before transaction costs. Simultaneously, 25,053,288 warrants of series TO14B are being issued, which could raise an additional SEK 7.5 million upon full subscription. The funds will be used to expand the workforce, increase production volumes, and intensify sales and marketing efforts in existing and new markets.
  • iZafe Group’s partner, Zafe Care Systems AB, has won a contract with Kristianstad Municipality for the delivery of 150-190 Dosell units, with a total order value of approximately SEK 3.7-4.3 million. The agreement spans four years, from 2024 to 2028.

Significant events after the end of the quarter

  • iZafe Group AB has received a confirmed order for 500 Dosell units from its partner Ti medi, with planned delivery to Spain in August 2024. The Dosell units will be integrated into Ti medi’s new concept, which combines their pouch packaging machines with the Dosell medication robot to enhance patient medication adherence through pharmacies in Spain.
  • iZafe Group AB has decided to enter into a loan agreement of SEK 5.5 million with Exelity AB instead of proceeding with the previously planned warrant exercise, TO14B, due to high costs and financial uncertainty. The issued warrants will therefore be canceled. The loan will be used to increase production volumes and strengthen sales and marketing activities to drive sales in both existing and new markets.

Comments from CEO
Dear shareholders, customers, and employees,

Our journey to revolutionize healthcare through innovation and digitalization continues to yield concrete progress and positive results. During the second quarter, we have experienced the most accelerated demand for our products to date, further strengthening our market position.

We have recently produced 500 Dosell units, which have been invoiced to our partner in Spain. The delivery will take place at the end of August, and the revenue from this order will be recognized upon delivery. Our partner, Ti-Medi, plans to launch Dosell in Spain according to the previously communicated customer journey at the end of the third quarter, which means that we expect to see the first active Dosell units in the Spanish market and the associated revenues starting from the fourth quarter.

In the Swedish market, we are now witnessing a clear upswing during Q2. The demand for our solutions is increasing significantly, and we have already won a tender for 150 units in Kristianstad. Together with our existing projects with the Västra Götaland Region and other municipalities, we plan to begin the implementation of Dosell in 25 municipalities across Sweden in the coming quarter. This means that more organizations will benefit from our solution to ensure the right medication is administered at the right time.

Our expansion in the Netherlands continues to progress despite previous challenges. We experienced disruptions in our supplier’s network connectivity during the quarter, which affected the operation of the Dosell units. Our network provider has now resolved these issues, but we are working in parallel to switch to a new provider to ensure maximum operational reliability going forward. TCCN, our new dedicated partner in the Netherlands, has taken over the market’s previous contracts and is making a significant investment in Dosell by opening a dedicated office and developing a platform that integrates with Dosell for a unique packaging solution that has been very well received by customers. We have so far delivered over 1,000 units to the Netherlands and look forward to increasing our presence with more units this fall.

The new Dosell 3.0, which has now been produced and delivered in collaboration with our new production partner, marks an important milestone for us and future-proofs the market. During Q2, we secured the production of an additional 1,500 units, of which 500 are destined for Spain and 150 for Kristianstad. This enables us to quickly meet the growing demand in both the Dutch and Nordic markets.

To ensure that we can meet the increasing demand and continue our growth journey, we have also secured a loan of SEK 5.5 million. The decision to replace a planned warrant exercise with this loan ensures that we can focus on scaling up production and strengthening our recurring revenue, which is central to our long-term success.

We also look forward to launching the markets in Norway and Finland this fall, in collaboration with our partners there, who have now further dedicated their commitment to Dosell. This, together with our strong position in Sweden and the Netherlands, positions us for an exciting period with many new opportunities and expansions.

On October 1st, we welcome our new CFO, who will be a key player in our swift pursuit of profitability. With the increased sales we are now seeing, our goal is to achieve cash flow positivity as soon as possible.

I would like to conclude by thanking all our employees, partners, and shareholders for your continued support and commitment. Together, we are heading towards a bright future with continued strong growth and innovation in sight.

Thank you for being part of our journey.

Anders Segerström
Chief Executive Officer, iZafe Group

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.

iZafe Group AB ("iZafe Group" or the "Company"), a company engaged in the research, development, and marketing of digital medical solutions and services for safer medication management at home, announce today that the Board of Directors of iZafe Group has decided to enter into a loan agreement of SEK 5.5 million (the "Loan") issued by Exelity AB (the "Lender"). The Loan has been secured because the board has determined that the issuance of the warrants of series TO14B (the "Warrants") would entail excessive administrative costs and financial uncertainty.

Background and rationale for the Loan
In connection with a directed issue conducted on April 9, 2024, the board of iZafe Group, with the authorization granted by the annual general meeting on May 16, 2023, decided to issue 25,053,288 warrants of series TO14B. These warrants were intended to be issued free of charge to the Company, which would then transfer them free of charge to the shareholders of the Company in proportion to the number of shares each shareholder owned on the record date for the warrant issue.

Since the decision was made, new information has been provided to the Company, revealing that the warrant issue would entail significantly higher costs than previously indicated. Given the financial uncertainty associated with the outcome of the warrants, the board of iZafe Group has decided that it is more advantageous for the Company to cancel the issued Warrants and instead secure the Loan.

iZafe Group's CEO, Anders Segerström, comments on the Loan: "Considering the new information we have received and the uncertainty that the warrant exercise would entail, we are convinced that the decision to replace the warrant exercise with this loan is the best solution for iZafe Group. This decision ensures the necessary financing to continue our growth journey and meet the increasing demand for our products. By scaling up production and strengthening our recurring revenue, which is at the core of our business model, we are creating significant value over time.

Our original ambition with the directed issue and the warrant exercise was to raise SEK 10 million, and although the conditions have changed, we have found a stable and sustainable solution with this loan. This will provide us with the financial stability and resources we need to increase sales and strengthen our recurring license revenue, which is crucial for achieving a cash flow-positive result."

Loan terms
The Loan amounts to SEK 5.5 million. The payment occurs upon signing of the loan agreement. The Loan matures for payment on June 30, 2025.
The Loan is subject to a set-up fee of 5.0 percent of the Loan amount and carries a monthly interest rate of 1.3 percent on the borrowed amount. Interest accrues from the payment until the loan amount and accrued interest are fully repaid. The Company has the option to repay the Loan before the maturity date without any redemption fee. The Lender has the right to convert the Loan into shares of the Company at any time during the term at a subscription price of SEK 0.24 per share. The board has assessed the loan terms as market competitive and considers taking the Loan to be in the best interest of both the Company and its shareholders.

Use of the Loan
The net proceeds from the Loan are intended to be used for the following purposes:

  • Ensuring larger production volumes
  • Sales and marketing activities to boost sales in existing and new markets

Advisor
Mangold Fondkommission AB is financial advisor to the Company in connection with the Loan.

Important information
The publication, disclosure, or distribution of this press release may be subject to restrictions under law in certain jurisdictions. Recipients of this press release in jurisdictions where it has been published, disclosed, or distributed should acquaint themselves with and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in their respective jurisdiction. This press release does not constitute an offer to, or an invitation to, acquire or subscribe for any securities in iZafe Group in any jurisdiction, either from the Company or any other entity.

This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration or an applicable exemption from registration under the U.S. Securities Act of 1933 ("Securities Act"), and may not be offered or sold in the United States without being registered, exempt from registration, or in a transaction not subject to the registration requirements of the Securities Act. There is no intention to register any securities mentioned herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be published, disclosed, copied, reproduced, or distributed, directly or indirectly, in whole or in part, in or to the United Kingdom, the United States, Canada, Japan, Australia, Belarus, Hong Kong, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea, or any other jurisdiction where such publication, disclosure, or distribution of this information would violate applicable laws and regulations.

Within the European Economic Area, no offer is made to the public of securities in any country other than Sweden. In other member states of the European Union, such an offer can only be made in accordance with an exception in the Prospectus Regulation (EU) 2017/1129.

Forward-Looking statements
This press release contains certain forward-looking information that reflects the Company's current view of future events as well as financial and operational development. Words such as "intended", "assessed", "expected", "may", "plans", "believes", "estimates", and other expressions that imply indications or predictions about future development or trends, and which are not based on historical facts, constitute forward-looking information. Forward-looking information is by its nature associated with both known and unknown risks and uncertainty factors because it depends on future events and circumstances. Forward-looking information does not constitute any guarantee regarding future results or development, and the actual outcome may materially differ from what is stated in the forward-looking information.

iZafe Group AB ("iZafe Group") today announces the receipt of an official order for 500 units of Dosell from Ti Medi, a dedicated partner of iZafe Group since April 2023. These units have recently been produced and will be delivered to Spain in August 2024, in time for Ti Medi's planned launch this fall of their new unique concept for the Spanish market.

Ti Medi, in collaboration with its 1400 pharmacies, will launch an innovative solution that combines their dose packaging machines with the Dosell medication robot. Pharmacies, which currently order dose packaging machines from Ti Medi, will now be able to offer consumers a complete solution where Dosell is delivered together with the dose bags produced by Ti Medi's machines. This integrated system will enable the consolidation of all data, allowing pharmacists to monitor patients' medication adherence in a new and efficient manner.

"We are delighted to collaborate with iZafe Group and to include Dosell in our new concept for the Spanish market. With this new customer journey, we can now combine our dose packaging machines with the Dosell medication dispenser, thereby offering our pharmacies a unique and comprehensive innovative solution that will improve patients' adherence to their medication," says Marc Tarruell Tibau, CEO of Ti Medi.

"After a year of dedicated work with Ti Medi, we are now seeing tangible results from our efforts to create a targeted customer journey for the Spanish market. This order demonstrates the high efficiency of our joint venture, and we are pleased that the Spanish market can now begin using Dosell. Our technology and capacity, combined with the simplicity of our solution, will make a real difference for both pharmacists and patients," says Anders Segerström, CEO of iZafe Group.

iZafe Groups VD Anders Segerström presenterade bolaget på Aktiespararnas evenemang Aktiedagarna den 11 juni.

Presentationens höjdpunkter inkluderade:

  • Lansering av Dosell 3.0: En uppdaterad version med kraftfullare processor och nya funktioner för att förbättra medicineringshantering och patientföljsamhet.
  • Marknadsutveckling: Betydande framsteg på flera europeiska marknader inklusive Sverige, Nederländerna, Spanien och andra länder.
  • Affärstillväxt: Stark organisk tillväxt och en hållbar affärsmodell med fokus på att minska vårdkostnader och förbättra patientsäkerheten.

Presentationen kan du se här.
Du hittar även denna presentation samt tidigare presentationer här.

iZafe Group (publ.) hereby announces that CEO Anders Segerström will present on Tuesday, June 11 at 11:45 AM at Stora Aktiedagarna in Stockholm.

On Tuesday, June 11 at 11:45 AM, iZafe will present its business at Stora Aktiedagarna in Stockholm. The address is Birger Jarlsgatan 61 A. The presentation will also be broadcast live and available afterwards on Aktiespararna's YouTube channel as well as on iZafe's website.
 
More information can be found via this link: https://www.aktiespararna.se/aktiviteter/aktiedagarna-i-stockholm-42149

Webbdesign av Comlog Webbyrå Stockholm